Form 4: Teva Pharmaceutical Industries: Chief Accounting Officer Reports Share Transactions

Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports the vesting and acquisition of restricted share units, as well as the disposition of ordinary shares, on March 5, 2025.

Summary

• On March 5, 2025, Amir Weiss, the Chief Accounting Officer of Teva Pharmaceutical Industries, engaged in transactions involving the company's shares.
• Weiss acquired 3,566 ordinary shares through the vesting of restricted share units.
• Weiss also disposed of 30,250 ordinary shares.
• Additionally, Weiss acquired 14,150 restricted share units, which will vest in future years.
• Following these transactions, Weiss directly owns 14,150 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reporting insider transactions. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The document outlines the vesting schedule for restricted share units granted to the Chief Accounting Officer, indicating future potential share acquisitions.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's a standard practice for publicly traded companies like Teva.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The vesting schedules for restricted share units are common compensation tools used across the pharmaceutical industry to incentivize and retain key personnel.
• Companies like Pfizer, Johnson & Johnson, and Novartis also regularly disclose similar insider transactions.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders due to the change in beneficial ownership.
• The vesting of restricted share units serves as an incentive for the Chief Accounting Officer, potentially impacting employee morale and retention.

Key Dates